|1.||Levkovitz, Yeciel: 1 article (04/2011)|
|2.||Papakostas, George I: 1 article (04/2011)|
|3.||Tedeschini, Enrico: 1 article (04/2011)|
|4.||Brochu, Richard M: 1 article (04/2007)|
|5.||Priest, Birgit T: 1 article (04/2007)|
|6.||Purohit, Yamini: 1 article (04/2007)|
|7.||Dick, Ivy E: 1 article (04/2007)|
|8.||Martin, William J: 1 article (04/2007)|
|9.||Kaczorowski, Gregory J: 1 article (04/2007)|
|10.||Strac, D S: 1 article (12/2006)|
04/01/1986 - "Twenty patients with chronic pain of non-malignant origin (mean duration 15.8 years) were entered into a double blind cross-over study of the analgesic efficacy of zimelidine and placebo. "
12/01/1979 - "Visual evoked potentials as a predictor of reported side effects during a trial of zimelidine vs. placebo in chronic pain patients."
08/01/1979 - "A double-blind controlled study of seratonin uptake inhibitor (Zimelidine) versus placebo in chronic pain patients."
04/01/1986 - "Zimelidine was superior (P less than 0.05) to placebo with respect to pain relief based on a global assessment (by the clinical investigators) performed at the completion of each treatment phase. "
01/01/1980 - "The results also indicate that treatment with Zimelidine may result in a decreased sensitivity to noxious stimulation that should be reflected in relief of clinical pain syndromes."
|2.||Depressive Disorder (Melancholia)
05/01/1986 - "The present results suggest that zimelidine may be more effective in the treatment of severely depressed patients, rather than those with more mild mixed anxiety/depressive syndromes."
01/01/1982 - "An open trial of zimelidine in patients with endogenous depression."
01/01/1984 - "Thirty-nine (39) patients entered a double blind study conducted to compare the therapeutic efficacy and safety of Zimelidine and amitriptyline in endogenous depression. "
01/01/1984 - "Double blind study comparing the efficacy of zimelidine and amitriptyline in endogenous depression."
01/01/1983 - "The aim of this study was to evaluate the safety of zimeldine, a 5-HT reuptake inhibitor, in the long-term treatment of depressive disorders. "
|3.||Major Depressive Disorder (Major Depressive Disorders)
01/01/1983 - "The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders was evaluated in a randomized, placebo-controlled study involving 40 patients. "
01/01/1983 - "The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders--a double-blind placebo-controlled study."
02/01/1983 - "Twenty-eight hospital inpatients with a primary major depressive disorder were treated with either zimelidine or placebo. "
01/01/1983 - "A multicentre double-blind comparative trial of zimeldine and imipramine in primary major depressive disorders."
01/01/1982 - "A double-blind, randomized clinical study was conducted in thirty-four out-patients suffering from major depressive disorders comparing zimelidine with amitriptyline. "
|4.||Alcoholism (Alcohol Abuse)
01/01/1986 - "Zimelidine, however, has no anticholinergic effect, so it is unlikely that cholinergic mechanisms thought to be important in animal cataplexy would play a major role in human cataplexy. "
01/01/1986 - "The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients."
12/01/1993 - "This, however, is an apparent contradiction to data obtained in human patients, which show that chronic oral administration of serotonergic uptake inhibitors, such as clomipramine, zimelidine and fluoxetine, is effective in reducing cataplexy. "
|4.||Levodopa (L Dopa)
|10.||Serotonin (5 Hydroxytryptamine)